Are The Clouds Going To Clear For MasTec, Inc. (MTZ), Platform Specialty Products Corp (PAH) and Spectrum Pharmaceuticals, Inc. (SPPI)?

Posted by admin May 13, 2015 0 Comment 565 views


New York, NY – GDP INSIDER  –  05/13/2014.

This article discusses three companies: MasTec, Inc. (NYSE:MTZ), Platform Specialty Products Corp (NYSE:PAH) and Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

MasTec, Inc. (NYSE:MTZ) declined yesterday with the stock hitting a new one year low of $15.34 before recovering to $16.19 by the end of trading, down 12.25% or $2.26 with more than 7.53 million shares changing hands compared to its 30 day average trading volume of 0.909 million. The stocks started to drop after it missed analysts’ earnings estimates in its first quarter. The company reported earnings of $0.07 per share for the quarter, which missed analysts’ estimate of $0.18 per share by $0.11. With RSI of 30.50 and one year price target estimate of $28.06, the infrastructure construction company has plenty of upside potential, hold with a view to buy.

Is It Risky To Invest In MasTec, Inc Now? Click Here To Read Our Free MTZ Analysis Here.

Platform Specialty Products Corp (NYSE:PAH) dropped yesterday as the stock lost 4% or $1.10 to finish the day at a closing price of $26.39 on higher than average trading volume of 2.65 million, compared to its three month average trading volume of 1.13 million. The sell off started after the company announced a net loss of $26.7 million or $0.21 per diluted share in its first quarter financial results. Platform Specialty Products Corp posted revenue of $534.60 million, which missed analysts’ estimate of $566.60 million by $31.8 million. With its RSI declining and MACD diverging in bearish direction, it is better to hold for now.

Is Platform Specialty Products Corp A Good Medium Term Investment? Delve Into Details With Free PAH Analysis.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) continued its recent upward trend yesterday closing up 10.07% or $0.61 to finish the day at $6.67 on heavy trading of 3.801 million shares compared with its three month average trading volume of 1.38 million. The biotechnology company has been steadily declining for the last one year with the stock down 12.12%, but has been started to gain back some of these losses since the beginning of the month with the stock up 10.43%. The current gains have widened the positive MACD divergence and pushed its RSI to 67, indicating that it may correct downwards in the near term, but still looks a solid hold at the moment.

Click Here For Free Spectrum Pharmaceuticals, Inc Analysis And See Whether SPPI Can Bolster Its Success.

About Ultimate Stock Alerts

UltimateStockAlerts.com covers NASDAQ and NYSE listed companies that are overlooked by Wall Street. Investors can choose to receive trading strategies via text message (SMS) or email. To receive free text message alerts text the word ULTIMATE to 555888 from your cell phone. For more information visit www.UltimateStockAlerts.com

Disclosure:  UltimateStockAlerts.com is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.


Write Your Comment